DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $297,402 | -29.0% | 14,416 | +1.5% | 0.00% | -100.0% |
| Q2 2023 | $419,071 | +75.8% | 14,201 | +37.2% | 0.00% | – |
| Q1 2023 | $238,418 | +14.8% | 10,348 | +38.5% | 0.00% | – |
| Q4 2022 | $207,713 | -7.3% | 7,469 | +2.5% | 0.00% | – |
| Q3 2022 | $224,000 | +7.7% | 7,288 | +3.0% | 0.00% | – |
| Q2 2022 | $208,000 | -4.6% | 7,075 | +4.4% | 0.00% | – |
| Q1 2022 | $218,000 | -6.0% | 6,780 | +30.2% | 0.00% | – |
| Q4 2021 | $232,000 | -11.8% | 5,208 | 0.0% | 0.00% | – |
| Q3 2021 | $263,000 | -33.8% | 5,208 | -53.0% | 0.00% | -100.0% |
| Q3 2020 | $397,000 | – | 11,080 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |